Floatz logo

Hryz-T101 Tcr-T Cell

Carcinoma of Vulva

HRYZ Biotech Co.Cell therapyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
89/ 100

Competitive context

9 Active assets in the Carcinoma of Vulva cohort.

Asset / SponsorPhaseRating
Cyclophosphamide
HRYZ Biotech Co.
Phase 2B
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril
Emory University
Phase 2CCC
Nivolumab
National Cancer Institute (NCI)
Phase 2CCC
Ipilimumab
National Cancer Institute (NCI)
Phase 2CCC
Pembrolizumab
Merck Sharp & Dohme LLC
Phase 2CCC

View all 19 →

Same molecule, other indications

Hryz-T101 Tcr-T Cell is also rated in:

oropharyngeal carcinomaDormant
CC
Indicative ·
43 / 100
View asset →
vaginal neoplasmDormant
CC
Indicative ·
43 / 100
View asset →
penile carcinomaDormant
CC
Indicative ·
43 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →